Evaluation of maintenance treatment with PARP inhibitors in ovarian carcinoma patients responding to platinum therapy: Use of restricted mean survival time as an index of efficacy

CONCLUSION: Maintenance therapy studies provide evidence that olaparib, niraparib, rucaparib are effective treatments for advanced ovarian cancer.PMID:34779394 | DOI:10.5414/CP204113

Source: International Journal of Clinical Pharmacology and Therapeutics - November 15, 2021 Category: Drugs & Pharmacology Authors: Luca Cancanelli Daniele Mengato Lorenzo Di Spazio Melania Rivano Marco Chiumente Andrea Messori Source Type: research